Esperion Therapeutics Inc. (Nasdaq: ESPR), an early-stage pharmaceutical company developing a new class of cholesterol-fighting drugs, Monday provided financial figures and a corporate update.
Police in Hawaii have identified human remains found in a remote area of a volcano as belonging to a metro Detroit man reported missing nearly six years ago.
Rofin-Sinar Technologies Inc. (Nasdaq: RSTI), the industrial laser maker with dual headquarters in Plymouth and Hamburg, Germany, reported financial results for the third fiscal quarter and nine months ended June 30.
Six more Michigan companies in industries ranging from bicycles to off-grid power to high-tech health have received investments from the Michigan Pre-Seed Capital Fund, totaling $1.5 million.
Comcast, Michigan’s No. 1 cable TV provider, Tuesday announced the Michigan launch of Xfinity Home Control, a new product under the Xfinity Home umbrella of services.
The Concours d’Elegance kicks off Sunday in Plymouth — where beautiful, classic and exotic automobiles will be on display.
Burroughs Inc. Thursday announced a software distributor agreement with Sullivan, Ill.-based Jaguar Software Development Inc. to sell and distribute its MirrorImage suite of application modules which can be configured to handle different item processing environments in the financial industry.
Esperion Therapeutics Inc. (Nasdaq: ESPR), the Plymouth-based developer of new drugs to lower cholesterol levels in the blood, announced that the underwriters of its recently completed initial public offering have exercised in full their option to purchase an additional 750,000 shares of common stock from Esperion to cover over-allotments.
PLYMOUTH — For the second time, a Michigan company called Esperion Therapeutics is selling stock to the public. Esperion Wednesday announced a $14-a-share price for an initial public offering of 5 million shares. Esperion is […]
Esperion Therapeutics Inc. Friday announced “positive” results from a Phase 2a clinical study of its product candidate ETC-1002 in patients with high cholesterol and a history of bad reactions to existing statin drugs.